^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-15025

    i
    Other names: BGB-15025, BGB15025, BGB 15025
    Associations

    News

    Trials
    Company:
    BeiGene
    Drug class:
    HPK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=100 --> 35 | Trial completion date: May 2026 --> Dec 2024 | Trial primary completion date: Jan 2026 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    docetaxel • Cyramza (ramucirumab) • BGB-15025 • BGB-A445
    6ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • zanidatamab (ZW25) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
    6ms
    BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, BeiGene | Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • BGB-15025
    10ms
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=400, Recruiting, BeiGene | N=200 --> 400
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • LBL-007
    11ms
    BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • BGB-15025
    1year
    A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • Cyramza (ramucirumab) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445
    1year
    HPK1 Inhibition Enhancing HFRT Anti-Tumor Immune Response. (PubMed, Int J Radiat Oncol Biol Phys)
    Thus, we demonstrate that HPK1 mediates HFRT-induced CD8+T cell exhaustion by regulating RGS16, and HPK1 is an attractive drug target for enhancing local and systemic radiotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    BGB-15025
    1year
    HPK1 Inhibition Enhances HXRT Anti-Tumor Immune Response by Regulating RGS16 to Restore Functionality in Tumor-Infiltrating Exhausted CD8+T Cells (ASTRO 2023)
    Thus, we demonstrate that HPK1 mediates HFRT-induced CD8+T cell exhaustion by regulating RGS16, and HPK1 is an attractive drug target for enhancing local and systemic radiotherapy.
    IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    BGB-15025
    over2years
    BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models (AACR 2022)
    Moreover, BGB-15025 demonstrated combination effect with anti-PD-1 antibody in CT26 and EMT-6 syngeneic tumor models. BGB-15025 is currently in phase I clinical trial to treat patients with advanced solid tumor, both as a single agent and in combination with anti PD-1 antibody tislelizumab.
    Preclinical • Combination therapy
    |
    IL2 (Interleukin 2) • LCP2 (Lymphocyte cytosolic protein 2)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-15025